Industry Updates
Industry Updates
AMA yet to ask regulatory agencies to block the $69 billion acquisition of Aetna by drugstore giant CVS Health
Unlike its more aggressive stance against health insurance mergers, the American Medical Association has yet to ask Congress and regulatory agencies to block the $69...
Press Releases
CVS Health amongst 2018 World’s Most Innovative Companies List: Fast company
CVS Health , the nation's largest pharmacy innovation company, was recognized today by Fast Company as one of the World's 50 Most Innovative Companies List...
Press Releases
Mckesson speciality health collaborates with Cryoport to enhance logistics services to shore up commercialization of cell and Gene therapies
McKesson Specialty Health, a division of McKesson Corporation, announced a strategic collaboration with Cryoport, Inc. designed to further strengthen its robust logistics services to support...
Press Releases
New Late-Breaking XARELTO® (rivaroxaban) and INVOKANA® (canagliflozin) Data to be Presented at the American College of Cardiology’s Annual Scientific Session
New studies and late-breaking analyses from the Janssen Pharmaceutical Companies of Johnson & Johnson are among the 11 company abstracts accepted for presentation at the...
Press Releases
Cega creates new role to meet rising demand for private repatriation
CEGA, the repatriation, medical assistance and claims provider, has appointed a new business development manager to meet the rising demand for private medical repatriations from...
Press Releases
ACG keen to Improve Technology for Authentication and Traceability of Capsules for the Pharmaceutical and Nutraceutical Industry: Signs Letter of Intent with Applied DNA...
Molecular labeling of capsules is intended to prevent counterfeiting The Letter of Intent between Applied DNA Sciences, Inc. and ACG grants ACG the rights to...
Press Releases
An additional FDA approval for Lilly’s Verzenio™ (abemaciclib), initial treatment for advanced breast cancer
Eli Lilly and Company announced that the U.S. FDA has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.